Unlike in CML, where TP53 mutations are linked to disease progression to blast crisis, in CLL, they are associated with poor response to chemoimmunotherapy, particularly to purine analogs such as fludarabine. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.